Last reviewed · How we verify
Corflazine (LIDOFLAZINE)
Corflazine (generic name: LIDOFLAZINE) is a lidoflazine drug. It is currently in Phase 2 development.
Corflazine works by blocking potassium channels in the body, which helps to regulate the electrical activity of cells.
Corflazine, also known as LIDOFLAZINE, is a small molecule drug that targets the potassium voltage-gated channel subfamily H member 2. It is classified as a lidoflazine drug and works by modulating ion channels to affect cellular excitability. However, due to the lack of available information, its commercial status, approved indications, half-life, bioavailability, and generic manufacturers are unknown. As a result, its FDA approval status and off-patent status also remain unclear. Further research is necessary to fully understand the properties and applications of Corflazine.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LIDOFLAZINE |
|---|---|
| Drug class | lidoflazine |
| Target | Equilibrative nucleoside transporter 1, Potassium voltage-gated channel subfamily H member 2, Sodium channel alpha subunits; brain (Types I, II, III) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Think of your body's cells like tiny electrical circuits. Potassium channels help control the flow of electrical signals within these circuits. By blocking these channels, Corflazine helps to slow down the electrical activity of cells, which can be beneficial in certain medical conditions.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corflazine CI brief — competitive landscape report
- Corflazine updates RSS · CI watch RSS
Frequently asked questions about Corflazine
What is Corflazine?
How does Corflazine work?
What is the generic name of Corflazine?
What drug class is Corflazine in?
What development phase is Corflazine in?
What does Corflazine target?
Related
- Drug class: All lidoflazine drugs
- Target: All drugs targeting Equilibrative nucleoside transporter 1, Potassium voltage-gated channel subfamily H member 2, Sodium channel alpha subunits; brain (Types I, II, III)
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing